ArticleJournal of the American Chemical Society2026
Solid-Phase Glycolipid Synthesis Expedites Liposome Functionalization.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycolipids play important roles in immune modulation, which makes them attractive components for vaccine delivery systems. However, access to these molecules remains a major limitation as most synthetic approaches rely on arduous solution-phase strategies. Here, we report a unified solid-phase platform that combines automated glycan assembly and iterative amide couplings for the rapid on-resin generation of a variety of mannan- and Gb3-derived glycolipids. This modular method enables the systematic diversification of glycan and lipid-anchor domains within a single synthetic framework. The synthetic constructs were used to generate glyco-functionalized liposomal nanoparticles with potential for immune cell targeting. Preliminary biological studies demonstrate efficient cell-associated uptake by antigen-presenting cells and show that biological performance is governed not only by glycan identity but also by anchor architecture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.